Home › NDC Lookup › RxCUI directory › RxCUI 790290

24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet [Pristiq] — RxCUI 790290

RxNorm drug concept · Semantic branded drug
RxCUI 790290 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI790290
Official name24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet [Pristiq]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as24 HR Pristiq 50 MG Extended Release Oral Tablet; Pristiq 50 MG 24HR Extended Release Oral Tablet; Pristiq 50 MG (as desvenlafaxine succinate 76 MG) 24 HR Extended Release Oral Tablet
FDA products mapped3
Package NDCs mapped9
Reported Medicaid activity (SDUD)6,922 prescriptions · 16 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Desvenlafaxine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats major depressive disorder in adults. It is an SNRI, which works on the brain chemicals serotonin and norepinephrine.
  • Take one tablet by mouth once a day at about the same time, with or without food. Swallow it whole with fluid. Don't split, crush or chew it. Follow your prescriber's directions.
  • Nausea, dizziness, trouble sleeping, sweating, constipation, sleepiness, dry mouth and lower appetite are common. Sexual side effects can also happen. Call your doctor if they are...
  • Please don't stop suddenly. Stopping abruptly can cause discontinuation symptoms, so your prescriber will usually lower the dose gradually.
📖 Read our full Desvenlafaxine guide →

🕸️ Concept Web — How 24 HR desvenlafaxine succinate 50 MG Extended Re... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet [Pristiq] RxCUI 790290

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Desvenlafaxine 734064
    • Desvenlafaxine succinate 683693
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pristiq 711372
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Desvenlafaxine Extended Release Oral Tablet 790263
    • Desvenlafaxine succinate Extended Release Oral Tablet 2648691
    • Desvenlafaxine Oral Product 1154233
    • Desvenlafaxine Pill 1154234
    • Desvenlafaxine succinate Oral Product 2659420
    • Desvenlafaxine succinate Pill 2659592
    • Desvenlafaxine Extended Release Oral Tablet [Pristiq] 790266
    • Desvenlafaxine succinate Extended Release Oral Tablet [Pristiq] 2655111
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet SCD · 1874559
  • Desvenlafaxine succinate 50 MG SCDC · 1874558
  • Desvenlafaxine Extended Release Oral Tablet SCDF · 790263
  • Desvenlafaxine succinate Extended Release Oral Tablet SCDFP · 2648691
  • Desvenlafaxine Oral Product SCDG · 1154233
  • Desvenlafaxine Pill SCDG · 1154234
  • Desvenlafaxine succinate Oral Product SCDGP · 2659420
  • Desvenlafaxine succinate Pill SCDGP · 2659592

Brand-Name Concepts

  • Desvenlafaxine succinate 50 MG [Pristiq] SBDC · 1874560
  • Desvenlafaxine Extended Release Oral Tablet [Pristiq] SBDF · 790266
  • Desvenlafaxine succinate Extended Release Oral Tablet [Pristiq] SBDFP · 2655111
  • Pristiq Oral Product SBDG · 1178920
  • Pristiq Pill SBDG · 1178921
  • Pristiq BN · 711372

📦 FDA Products & Package NDCs

3 products · 9 package NDCs
9 package NDCs map to RxCUI 790290 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00008-1210-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1210-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2015-04-01
00008-1211-01 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1211-14 14 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1211-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1211-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1211-50 100 BLISTER PACK in 1 CARTON (0008-1211-50) / 1 TABLET, EXT... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1222-01 90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1222-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1222-14 14 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1222-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1222-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0008-1222-... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
00008-1222-50 100 BLISTER PACK in 1 CARTON (0008-1222-50) / 1 TABLET, EXT... Pristiq Extended-Release Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. 2008-05-01
Observed labelers: Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.